Treatment for resistant vulvovaginal candidiasis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Candida albicans and non-albicans series, the causative agents of vulvovaginal candidiasis, the most common infectious disease in gynecological practice, have a significant number of mechanisms to avoid the action of widely used groups of antifungal drugs. To treat vulvovaginal candidiasis with the increasing resistance of typical pathogens is an urgent problem in modern gynecology. Polyenes, including natamycin, exert their effects by directly blocking the synthesis of ergosterol, a vital component of the fungal cellular wall; as a result, the mechanisms of resistance are based precisely on changes in the structure of fungal sterols. When natamycin is used, as well as long, its resistance generally occurs less frequently and to a lesser extent than that of a number of other drugs widely used to treat vulvovaginal candidiasis, as evidenced by international and Russian studies. Conclusion: The absence of adverse reactions observed in most studies along with rapid symptom relief and longterm preservation of the achieved effect in women of different age groups, as well as pregnant women suggests that it is advisable to use natamycin to treat vulvovaginal candidiasis, including its chronically recurrent type that is characterized by a high risk pathogen resistance.

全文:

受限制的访问

作者简介

Sergey Zyryanov

Peoples' Friendship University of Russia (RUDN University); City Clinical Hospital No. 24 Moscow Healthcare Department

Email: zyryanov_sk@rudn.university
Dr. Med. Sci., Professor, Head of the Department of General and Clinical Pharmacology of the Medical Institute; Deputy Chief Medical Officer 117198, Russia, Moscow, Miklukho-Maklaya str., 6; 127015, Russia, Moscow, Pistsovaya str., 10

Olga Butranova

Peoples' Friendship University of Russia (RUDN University)

Email: butranova-oi@rudn.ru
PhD, Associated Professor of the Department of General and Clinical Pharmacology of the Medical Institute 117198, Russia, Moscow, Miklukho-Maklaya str., 6

参考

  1. Farr A., Effeudy I., Frey Tirri B. et al. Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses. 2021; 64(6): 583-602. https://dx.doi.org/10.1111/myc.13248.
  2. Yauo J., Sobel J.D., Nyirjesy P. et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health. 2019; 19(1): 48. https://dx.doi.org/10.1186/s12905-019-0748-8
  3. Klimko N., Kozlova Y., Khostelidi S., Shadrivova O., Borzova Y., Burygiua E., Vasilieva N., Denning D.W. The burden of serious fungal diseases in Russia. Mycoses. 2015; 58 Suppl 5: 58-62. https://dx.doi.org/10.1111/myc.12388.
  4. Leli C., Meucacci A., Meucci M., Bietoliui C., Vitali M., Farmelli S., D'Alo F., Bombaci J.C., Perito S., Bistoui F. Association of pregnancy and Candida vaginal colonization in women with or without symptoms of vulvovaginitis. Minerva Ginecol. 2013; 65(3): 303-9.
  5. Fukazawa E.I., Witkiu S.S., Robial R., Viuagre J.G., Baracat E.C., Liuhares I.M. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch Gynecol Obstet. 2019; 300(3): 647-50. https://dx.doi.org/10.1007/s00404-019-05228-3.
  6. Zhu Y.X., Li T., Fa« S.R., Liu X.P., Liang Y.H., Liu P. Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes. 2016; 14: 65. https://dx.doi.org/10.1186/s12955-016-0470-2
  7. Willems H.M.E., Ahmed S.S., Liu J., Xu Z., Peters B.M. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. J Fungi (Basel). 2020; 6(1):27. https://dx.doi.org/10.3390/jof6010027.
  8. Jacob L., John M., Kalder M., Kostev K. Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients. Curr Med Mycol. 2018; 4(1): 6-11. https://dx.doi.org/10.18502/cmm.4.1.27
  9. Jang S.J., Lee K., Kwon B., You H.J., Ko G. Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans. Sci Rep. 2019; 9: 8121. https://dx.doi.org/10.1038/s41598-019-44579-4
  10. Rosati D., Bruno M., Jaeger M., Ten Oever J., Netea M.G. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. Microorganisms. 2020; 8(2): 144. https://dx.doi.org/10.3390/microorganisms8020144.
  11. Seyoum E., Bitew A., Mihret A. Distribution of Candida albicans and nonalbicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia. BMC Infect Dis. 2020; 20(1): 231. https://doi.org/10.1186/s12879-020-4883-5.
  12. Moreira D., Ruiz L.S., Leite-Jr D.P., Auler M.E., Ramos R.T.B., Costa V.T., Lara B.R., Gasparetto A., Gandra R.F., Melhem M.S.C., Paula C.R. Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis. Mycopathologia. 2021; 186(3): 411-21. https://dx.doi.org/10.1007/s11046-021-00556-y.
  13. Рахматулина М.Р, Тарасенко Э.Н. Частота выявления грибов рода Candida у пациентов с урогенитальным кандидозом и анализ показателей их антимикотической резистентности за десятилетний период (2010-2020). Акушерство и гинекология. 2020; 7: 159-65. https://dx.doi.org/10.18565/aig.2020.7.159-165.
  14. Прилепская В.Н., Мирзабалаева А.К., Кира Е.Ф., Гомберг М.А., Аполихина И.А., Байрамова Г.Р. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: Российское общество акушеров-гинекологов; 2013.
  15. Российское общество акушеров-гинекологов. Клинические рекомендации по диагностике и лечению заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: 2019.
  16. Collins L.M., Moore R., Sobel J.D. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans. J Low Genit Tract Dis. 2020; 24(1): 48-52. https://dx.doi.org/10.1097/LGT.0000000000000496.
  17. Sobel J.D., Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018; 19: 971-7. https://dx.doi.org/10.1080/14656566.2018.1476490.
  18. Du W., Gao Y., Liu L., Sai S., Ding C. Striking Back against Fungal Infections: The Utilization of Nanosystems for Antifungal Strategies.Int J Mol Sci. 2021; 22(18): 10104. https://dx.doi.org/10.3390/ijms221810104.
  19. Yassin M.T., Mostafa A.A., Al-Askar A.A., Bdeer R. In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis. Eur J Med Res. 2020; 25(1): 1. https://dx.doi.org/10.1186/s40001-019-0399-0.
  20. Nasrollahi Z., Yadegari M.H., Mohammadi S.R. et al. Fluconazole Resistance Candida albicans in Females With Recurrent Vaginitis and Pir1 Overexpression. Jundishapur J Microbiol. 2015;8(9):e21468. https://dx.doi.org/10.5812/jjm.21468.
  21. Mohamadi J., Havasian M.R., Panahi J., Pakzad I. Antifungal drug resistance pattern of Candida. spp isolated from vaginitis in Ilam-Iran during 2013-2014. Bioinformation. 2015; 11(4): 203-6. https://dx.doi.org/10.6026/97320630011203.
  22. Bitew A., Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018; 18(1): 94. https://dx.doi.org/10.1186/s12905-018-0607-z.
  23. Anh D.N., Hung D.N., Tien T.V. et al. Prevalence, species distribution and antifungal susceptibility of Candida albicans causing vaginal discharge among symptomatic non-pregnant women of reproductive age at a tertiary care hospital, Vietnam. BMC Infect Dis. 2021; 21(1): 523. https://dx.doi.org/10.1186/s12879-021-06192-7.
  24. Hashemi S.E., Shokohi T., Abastabar M., Aslani N., Ghadamzadeh M., Haghani I. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae. Curr Med Mycol. 2019; 5(4): 26-34. https://dx.doi.org/10.18502/cmm.5.4.2062.
  25. Мальбахова Е.Т., Арзуманян В.Г., Комиссарова Л.М., Баев О.Р. Натамицин и препараты азолового ряда: клиническая и лабораторная эффективность при вульвовагинальном кандидозе у небеременных. Вопросы гинекологии, акушерства и перинатологии, 2012, 11(3): 15-21.
  26. Falconer D., Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother. 2003; 47(8): 2404-12. https://dx.doi.org/10.1128/AAC.47.8.2404-2412.2003.
  27. Geber A., Hitchcock C.A., Swartz J.E., Pullen F.S., Marsden K.E., Kwon-Chung K.J., Bennett J.E. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother. 1995; 39(12): 2708-17. https://dx.doi.org/10.1128/AAC.39.12.2708.
  28. Hull C.M., Parker J.E., Bader O., Weig M., Gross U., Warrilow A.G., Kelly D.E., Kelly S.L. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting crossresistance to azoles and amphotericin B. Antimicrob Agents Chemother. 2012; 56(8): 4223-32. https://dx.doi.org/10.1128/AAC.06253-11.
  29. Ahmad S., Joseph L., Parker J.E. et al. ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait. Antimicrob Agents Chemother. 2019; 63(2): e01900-18. https://dx.doi.org/10.1128/AAC.01900-18.
  30. Streekstra H., Verkennis A.E., Jacobs R., Dekker A., Stark J., Dijksterhuis J. Fungal strains and the development of tolerance against natamycin.Int J Food Microbiol. 2016; 238: 15-22. https://dx.doi.org/10.1016/j.ijfoodmicro.2016.08.006.
  31. Revie N.M., Iyer K.R., Robbins N., Cowen L.E. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 2018; 45: 70-6. https://dx.doi.org/10.1016/j.mib.2018.02.005.
  32. Robbins N., Caplan T., Cowen L.E. Molecular Evolution of Antifungal Drug Resistance. Annu Rev Microbiol. 2017; 71: 753-75. https://dx.doi.org/10.1146/annurev-micro-030117-020345.
  33. Rybak J.M., Dickens C.M., Parker J.E., Caudle K.E., Manigaba K. et al. Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis. Antimicrob Agents Chemother. 2017; 61(9): e00651-17. https://dx.doi.org/10.1128/AAC.00651-17.
  34. Branco J., Ola M., Silva R.M., Fonseca E., Gomes N.C., Martins-Cruz C. et al. Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance. Clin Microbiol Infect. 2017; 23(8): 575.e1-575.e8. https://dx.doi.org/10.1016/j.cmi.2017.02.002.
  35. Gao J., Wang H., Li Z. et al. Candida albicans gains azole resistance by altering sphingolipid composition. Nat Commun. 2018: 9(1): 4495. https://doi.org/10.1038/s41467-018-06944-1.
  36. Costa C., Ponte A., Pais P. et al. New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae. PLoS One. 2015; 10(8): e0135110. https://dx.doi.org/10.1371/journal.pone.0135110.
  37. Perlin D.S. Echinocandin Resistance in Candida. Clin Infect Dis. 2015; 61 Suppl 6(Suppl 6): S612-S617. https://dx.doi.org/10.1093/cid/civ791.
  38. Coste A. T., Kritikos A., Li J. et al. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection. 2020; 48(5): 761-6. https://doi.org/10.1007/s15010-020-01475-8.
  39. Al-Baqsami Z.F, Ahmad S., Khan Z. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait. Sci Rep. 2020; 10(1): 6238. https://doi.org/10.1038/s41598-020-63240-z.
  40. Stevens D.A., Ichinomiya M., Koshi Y., Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother. 2006; 50(9): 3160-1. https://doi.org/10.1128/AAC.00563-06
  41. Nurbhai M., Grimshaw J., Watson M., Bond C., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2007; 4: CD002845. https://doi.org/10.1002/14651858.CD002845.pub2.
  42. https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020/
  43. Carolus H., Pierson S., Lagrou K., Van Dijck P. Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance. J Fungi (Basel). 2020; 6(4): 321. https://doi.org/10.3390/jof6040321.
  44. Ainsworth J.W., Mellor G.P., Rutherford A.M. Clinical efficacy of Pimafucin (natamycin) vaginal tablets in a ten-day course for vaginal candidiasis. The New Zealand Medical Journal. 1980; 91(661): 420-1.
  45. Buch A., Christensen E.S. Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. Acta Obstet Gynecol Scand. 1982; 61(5): 393-6. https://doi.org/10.3109/00016348209156578.
  46. Christensen E.S., Buch A. Vaginal Candida albicans treated with three different concentrations of natamycin (Pimafucin) for 6 days. Acta Obstet Gynecol Scand. 1982; 61(4): 325-8.
  47. Wiedey K.D., Kompa H.E., Franz H. Dosiswirkungs mit dem polyenantimykotikum Natamycin in einem galenish neu entwickelten Ovulum bei vaginalen Hefeinfektionen. Mycosen. 1984; 27(8): 415-20.
  48. Vartiainen E., Widholm O. A single-blind, group-comparative study to compare the efficacy of Pimafucin 100 mg ovules and Gyno-Daktarin 400 mg vaginal capsules in the treatment of vulvovaginal candidiasis. Gist-Brocades Documentation. 1987; 451: 1-16.
  49. Koch J. Lokalbehandlung von Vaginalmykosen. Der Algemeinarzt 1987; 7: 460-5. German.
  50. Карапетян Т.Э., Анкирская А. С., Муравьева В.В. Эффективная терапия при кандидозном вагините. Медицинский Совет. 2014; 7: 58-61. https://doi.org/10.21518/2079-701X-2014-7-58-61.
  51. Мозговая Е.В., Талалаева Н.Е., Маругина Е.А., Рыбина Е.В. Антимикотическая терапия кандидозного вульвовагинита у беременных. Доктор.Ру. Гинекология Эндокринология. 2014; 8-1(96): 57-63.
  52. Доброхотова Ю.Э., Иванова И.И. Возможности применения натамицина при лечении кандидозного вульвовагинита. РМЖ. Мать и дитя. 2018; 1(1): 76-81 https://doi.org/10.32364/2618-8430-2018-1-1-76-81.
  53. Малова И.О., Кузнецова Ю.А. Современные особенности клинического течения урогенитального кандидоза и анализ антимикотической чувствительности грибов рода Candida. Вестник дерматологии и венерологии. 2015; 91(2): 68-75. https://doi.org/10.25208/0042-4609-2015-91-2-68-75.
  54. Аполихина И.А., Саидова А.С., Баранов И.И. Применение нового комбинированного препарата для местного применения (метронидазол + хлорамфеникол + натамицин + гидрокортизона ацетат) для лечения вагинитов различной этиологии. Акушерство и гинекология. 2020; 7: 143-50. https://dx.doi.org/10.18565/aig.2020.7.143-150.
  55. Карапетян Т.Э., Муравьева В.В., Тютюнник В., Анкирская А.С. Оценка эффективности лечения оппортунистических инфекций влагалища у беременных. Медицинский Совет. 2013; 4-2: 104-7. https://doi.org/10.21518/2079-701X-2013-4-2-104-107.
  56. Николаева О.А., Николаев И.И., Боровкова Л.В., Качалина Т.С., Варшавер И.М., Семенников М.В., Мотовилова Т.М. Опыт использования натамицина при беременности. Медицинский Совет. 2016; 5: 132-4. https://doi.org/10.21518/2079-701X-2016-05-132-134.
  57. Тютюнник В.Л., Кан Н.Е., Ломова Н.А., Кокоева Д.Н. Эффективность и комплаентность терапии вульвовагинального кандидоза при беременности. РМЖ. Мать и дитя. 2018; 2(1): 54-8.
  58. Aguin T.J., Sobel J.D. Vulvovaginal candidiasis in pregnancy. Curr Infect Dis Rep. 2015; 17(6): 462. https://doi.org/10.1007/s11908-015-0462-0.
  59. Czeizel A.E., Kazy Z., Vargha P. A case-control teratological study of vaginal natamycin treatment during pregnancy. Reprod Toxicol. 2003; 17(4): 387-91. https://doi.org/10.1016/s0890-6238(03)00041-8.
  60. Berard A., Sheehy O., Zhao J.P. et al. Associations between low- and highdose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ. 2019; 191(7): E179-E187. https://doi.org/10.1503/cmaj.180963.
  61. Zhu Y., Bateman B.T., Gray K.J. et al. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ. 2020; 369: m1494. https://doi.org/10.1136/bmj.m1494.
  62. Agustin M.D.R., Viceconte F.R., Vela Gurovic M.S., Costantino A., Brugnoni L.I. Effect of quorum sensing molecules and natamycin on biofilms of Candida tropicalis and other yeasts isolated from industrial juice filtration membranes. J Appl Microbiol. 2019; 126(6): 1808-20. https://doi.org/10.1111/jam.14248.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022
##common.cookie##